February 12, 2014. Testimony of Laurén Doamekpor, Senior Fellow with NCHR, on Cangrelor to the FDA Cardiovascular and Renal Drugs Advisory Committee.
Read More »On Medical Treatments & Products
NCHR Testimony to the FDA Advisory Committee Regarding Dapagliflozin (Farxiga)
December 12, 2013. NCHR expresses concerns about this drug that there are just too many unanswered questions – and those unanswered questions are frightening ones.
Read More »NCHR Testimony on Telavancin (VIBATIV) to FDA
November 29, 2012. Dr. Yttri testifies to the FDA that there is not sufficient evidence to support telavancin as a safe and effective treatment for nosocomial pneumonia. The data raise questions about a high mortality rate associated with telavancin.
Read More »NCHR Testimony on Computed Tomography Colonography
September 9, 2013. We agree with the Task Force that at this point, there is no reason to recommend virtual colonoscopies for most patients who need screening. We would add, however, that if specific patients are unwilling to undergo regular colonoscopies, then a virtual colonoscopy is a reasonable alternative.
Read More »Comments on Reclassification of External Counter-Pulsating Devices for Treatment of Chronic Stable Angina
August 19, 2013. We are writing as members of the Patient, Consumer, and Public Health Coalition to express our concerns about the proposed down-classification from Class III to Class II of External Counter-Pulsating (ECP) devices for treatment of chronic stable angina that is refractory to optimal anti-anginal medical therapy and without options for revascularization. We strongly support the proposed PMA for other indications for the same ECP devices.
Read More »